Cardiff Insights - Life Sciences Intelligence for the Week
Life Sciences M&A, Partnering & Capital Markets, Week of March 28- April 4, 2026
Welcome to Cardiff Insights. Happy Easter and hope you're having a wonderful long weekend on this time of reflection and renewal. This past week was one of the most prolific dealmaking weeks in biopharma in 2026: nine separate transactions worth over $20 billion announced in seven days, two $5B+ megadeals on a single Tuesday morning, Lilly’s landmark Foundayo FDA approval, the largest-ever private life sciences fund close, and a 100% pharmaceutical tariff executive order all against a backdrop of a U.S.-Iran military conflict driving Brent crude above $100. Let’s get into it.
I. MERGERS & ACQUISITIONS, DEALS AND PARTNERSHIPS
Nine separate biopharma transactions were announced or completed in the week of March 28–April 4, spanning neurology, allergy/immunology, CNS/psychiatry, autoimmune, oncology, and AI drug discovery. Combined deal value exceeded $20 billion. The week’s M&A landscape was reported across Endpoints News, Fierce Biotech, Fierce Pharma, BioPharma Dive, STAT News, GlobeNewswire, and Pharmaphorum.
Eli Lilly (NYSE: LLY) | Acquisition of Centessa Pharmaceuticals | $6.3B Upfront + $1.5B CVR (Up to $7.8B)
Target: Centessa Pharmaceuticals (Nasdaq: CNTA) | 40.5% premium to 30-day VWAP | Close Q3 2026
Lilly agreed to acquire Centessa for $38/share in cash plus a CVR worth up to $9/share tied to three FDA milestone triggers for Centessa’s orexin receptor 2 (OX2R) agonist portfolio. Lead drug cleminorexton (formerly ORX750) is in Phase 2a for narcolepsy types 1 and 2 and idiopathic hypersomnia. The orexin class directly compensates for the neuropeptide lost in narcolepsy patients; the class has multi-indication potential in Alzheimer’s, depression, and other fatigue-associated disorders. Centessa trails Takeda (oveporexton, FDA review) and Alkermes (alixorexton, Phase 3-ready) in timing but claims best-in-class differentiation. Lilly’s third acquisition of 2026 and largest since Loxo Oncology ($8B, 2019).
Cardiff View: Lilly pays a premium optionality price for a Phase 2a asset to build a CNS franchise ahead of competitors. The CVR structure efficiently bridges valuation uncertainty: $6.3B covers the platform value, with another $1.5B contingent on regulatory execution. CVRs are now standard in neuroscience deals where clinical proof-of-concept data exists, but full Phase 3 validation doesn’t. For boards evaluating neuroscience partnerships or sale processes: Lilly is an active acquirer in this space at Phase 2a entry points.
Otsuka Pharmaceutical | Acquisition of Transcend Therapeutics | $700M Upfront + $525M in Sales Milestones = $1.225B Total
Target: Transcend Therapeutics (private) | Close: Q2 2026 | FDA Breakthrough Therapy Designation (July 2025)
Otsuka agreed to acquire Transcend Therapeutics through its U.S. subsidiary for $700M upfront plus up to $525M in contingent sales milestone payments. Transcend’s lead asset TSND-201, is methylone, an analog of MDMA being developed as a neuroplastogen for PTSD, anxiety, and major depressive disorder. Unlike MDMA, TSND-201 does not act on the 5-HT2A serotonin receptor, eliminating hallucinogenic effects while retaining neuroplasticity-enhancing properties. Phase 2 IMPACT-1 data (published in JAMA Psychiatry, February 2026) showed significant PTSD symptom improvements at 64 weeks following just four once-weekly oral doses. Phase 3 recruitment is underway. Transcend received FDA Breakthrough Therapy designation in July 2025. Otsuka previously acquired Canada’s Mindset Pharma in 2024 for ~$65M in the same neuroplastogen space.
Cardiff View: This is a good comparable deal for the neuroplastogen/psychedelic-adjacent space and signals that mainstream pharma is now comfortable acquiring MDMA-class assets after Lykos’ MDMA failure in 2024 reset expectations. Transcend’s decision to remove hallucinogenic properties through molecular design rather than session-based therapy models may have been the decisive clinical and regulatory differentiator. At $700M upfront for Phase 2 data with Phase 3 underway, the deal values the Breakthrough Therapy designation meaningfully. For Cardiff clients developing neuropsychiatric or CNS assets, the Otsuka deal confirms that Japanese pharma has become an active acquirer in U.S. CNS at premiums comparable to Big Pharma.
Novartis (NYSE: NVS) | Acquisition of Excellergy Therapeutics | Up to $2B (Upfront + Milestones)
Target: Excellergy Therapeutics (Palo Alto, CA; raised $70M seed just 5 months prior) | Close: H2 2026
Novartis agreed to acquire Palo Alto-based Excellergy for up to $2B in combined upfront and milestone payments, gaining Exl-111, a next-generation anti-IgE antibody designed as a potential Xolair successor. Exl-111 works via a different mechanism than Xolair: rather than binding to free IgE in the bloodstream, it dissociates receptor-bound IgE and downregulates IgE receptor expression, a mechanism Novartis believes could offer faster, deeper suppression of allergic reactions with potentially less frequent dosing. Exl-111 is in Phase 1 development (DISARM trial, initiated February 2026). Xolair generated $1.7B in 2025 sales for Novartis; biosimilars are expected in U.S. markets in H2 2026. Remarkably, Excellergy had been in existence for just five months and raised only $70M in seed funding before this acquisition.
Cardiff View: The seed-to-$2B acquisition of a five-month-old biotech is one of the most striking deals of the quarter. It demonstrates that in validated therapeutic areas with obvious strategic logic (Xolair successor, Novartis’s franchise defense against biosimilars), large pharma will pay platform premiums even for pre-Phase 2 assets when the mechanism is compelling and the acquirer’s strategic need is urgent. The $70M seed round to $2B acquisition in five months is a case study in how quickly pharmaceutical acquirers can move when motivated. For Cardiff clients: if you have assets in validated but competition-threatened spaces (biosimilar cliffs, patent expiries), proactively marketing to the incumbent franchisee before biosimilar entry is a high-value strategy.
Eli Lilly (NYSE: LLY) + Insilico Medicine (HKEX: 3696) | AI Drug Discovery Partnership | $115M Upfront + Up to $2.75B in Milestones + Royalties
Insilico Medicine (Hong Kong-listed); third partnership between companies since 2023
Lilly signed a drug discovery collaboration with Hong Kong-listed AI biotech Insilico Medicine, granting Lilly an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of preclinical oral therapeutics generated by Insilico’s end-to-end Pharma.AI generative AI platform. Upfront payment: $115M. Total deal value: up to $2.75B in milestones plus tiered royalties. The companies will also co-run additional discovery programs targeting indications selected by Lilly. Notably, STAT News and BioPharmatrend reported that Insilico’s pipeline page was updated around the time of the deal to show a GLP-1 candidate as out-licensed, pointing to oral GLP-1 assets as a likely component of the licensed portfolio. This is the third partnership between Lilly and Insilico since their initial 2023 AI software licensing agreement, deepening to an asset licensing deal worth $100M in November 2025, and now this $2.75B commercialization deal. Insilico IPO’d on the Hong Kong Stock Exchange in December 2025, raising $293M, with Lilly as a cornerstone investor.
Cardiff View: One of the largest AI-to-commercial drug licensing deals in industry history and a validation of end-to-end generative AI drug discovery at scale. The likelihood that a GLP-1 oral candidate is among the licensed assets is the deal’s most commercially significant angle: if Insilico’s AI-discovered oral GLP-1 molecule is among the portfolio, this adds a ninth program to the increasingly crowded oral GLP-1 landscape. More broadly, the Lilly-Insilico deal at $115M upfront confirms that AI-discovered preclinical molecules are now valued at near-clinical-stage prices when the buyer has strong conviction. For Cardiff clients developing AI drug discovery platforms or AI-discovered assets: Lilly, Roche, AstraZeneca, and Sanofi are all active licensors. This deal should be a benchmark for your next licensing conversation.
Biogen (Nasdaq: BIIB) | Acquisition of Apellis Pharmaceuticals | $5.6B (86% Premium to 90-Day VWAP) + CVR on Syfovre
Target: Apellis Pharmaceuticals (Nasdaq: APLS) | Stock +135.7% on announcement | Close: mid-2026
Biogen agreed to acquire Apellis for $41/share in cash (86% premium to 90-day VWAP; 35% premium to 52-week high) plus a non-transferable CVR tied to Syfovre global net sales thresholds. Apellis’s stock had fallen 32% year-to-date through March 30 before the announcement. The deal brings Syfovre (geographic atrophy/AMD) and Empaveli (PNH and C3 glomerulopathy rare kidney disease): combined 2025 revenue ~$689M, growing mid-to-high teens. EPS accretion expected from 2027 with full de-lever by end of 2027. Biogen CEO Viehbacher described the deal as accelerating the company’s transformation in immunology and rare disease while deepening its nephrology franchise alongside felzartamab.
Cardiff View: Biogen paid a strategic price for a commercially validated asset with growing revenues that was temporarily punished by the market. The 86% premium to 90-day VWAP is the key signal: Biogen was not buying weakness, it was buying undervaluation. For Cardiff clients whose companies are in similar situations with proven commercial traction but suppressed stock, the Apellis deal demonstrates that well-resourced strategic acquirers will pay fair strategic value regardless of where the public market has temporarily priced an asset.
Aurinia Pharmaceuticals (Nasdaq: AUPH) | Acquisition of Kezar Life Sciences | ~$50M ($6.955/share Cash + CVR)
Target: Kezar Life Sciences (Nasdaq: KZR) | Acquirer CEO Kevin Tang (newly appointed) | Close: Q2 2026 | TD Cowen advised Kezar
Aurinia Pharmaceuticals agreed to acquire Kezar Life Sciences for $6.955 per share in cash plus a CVR entitling holders to: (1) potential payments from ongoing zetomipzomib development or disposition; (2) proceeds from Kezar’s Everest Medicines collaboration and the prior Enodia Therapeutics Sec61 asset sale; and (3) 100% of Kezar’s closing net cash. The deal values Kezar at just over $50M on ~7.3M shares outstanding. Kevin Tang, a veteran biotech acquirer and activist investor, was named Aurinia’s CEO just last week after serving as board chair since 2024; he previously made an unsuccessful attempt to acquire Kezar via Concentra Biosciences/Tang Capital in 2024 at $1.10/share during the clinical hold period. The dramatically higher current price ($6.95 vs. $1.10) reflects positive FDA Type C feedback on zetomipzomib in autoimmune hepatitis.
Cardiff View: A tenacious acquirer strategy that ultimately paid off for both sides: Tang’s $1.10 bid two years ago failed at the worst moment for Kezar, but he stayed close (joining the board) and returned when the FDA feedback improved. The CVR structure is creative and it allows shareholders to retain upside from the multiple Kezar monetization pathways without requiring Aurinia to front all the capital. For Cardiff clients and advisors, this deal illustrates the value of ‘staying in the game’ with target companies even after a failed initial offer: informed patience and board-level relationships create second-chance acquisition opportunities.
Johnson & Johnson + Royalty Pharma (Nasdaq: RPRX) | R&D Co-Funding Agreement | $500M (Across 2026–2027)
Drug: JNJ-4804, investigational IL-23/TNF dual co-antibody for chronic immune-mediated diseases
Royalty Pharma announced a $500M R&D co-funding agreement with Johnson & Johnson across 2026 and 2027 to advance JNJ-4804, a novel co-antibody that simultaneously blocks interleukin-23 (IL-23) and tumor necrosis factor (TNF) pathways, two of the most validated targets in autoimmune inflammation. In return, Royalty Pharma will receive royalties on future net sales if JNJ-4804 gains approval. Royalty Pharma CEO Pablo Legorreta noted the deal builds on the company’s existing royalty positions in TNF-targeting therapies. JNJ-4804 targets both pathways simultaneously, with potential to deliver synergistic effects in diseases where single-pathway blockade is insufficient.
Cardiff View: This is the Blackstone Life Sciences playbook applied by Royalty Pharma in immunology: pay for late-stage clinical development, receive royalties on commercial success. For J&J, the $500M over two years offsets clinical trial costs without equity dilution or asset disposition. The dual IL-23/TNF mechanism is clinically sound and both targets are approved independently (Tremfya for IL-23; Stelara, Humira for TNF), and combination blocking has biological rationale for refractory disease. For Cardiff clients: the Royalty Pharma and Blackstone models are now the two dominant alternative capital tools in late-stage pharma. Both reward high Phase 3 conviction assets with non-dilutive capital.
Lilly, Multiple Simultaneous Strategic Plays | Strategic Portfolio | $3B China + $500M South Korea + $2.75B Insilico AI
Endpoints News reported this week that Lilly CEO David Ricks’ deal-every-nine-days cadence continued into 2026 with three simultaneous strategic commitments: (1) Lilly/Insilico Medicine’s $2.75B AI drug discovery deal for oral therapeutics; (2) Lilly $500M/five-year MOU with South Korea Ministry of Health and Samsung Biologics for a Gateway Labs incubator; (3) Lilly’s $3B decade-long China manufacturing investment for orforglipron/GLP-1 supply chain. Additionally, Lilly’s Foundayo received FDA approval on April 1. Each commitment is a different dimension of Lilly’s strategy: AI-discovered molecules in, global manufacturing out, innovation hubs globally.
Cardiff View: Lilly is executing the most comprehensive strategic expansion in U.S. pharma, simultaneously building AI discovery capacity (Insilico, Nvidia), global manufacturing infrastructure (China, Puerto Rico), innovation sourcing (South Korea, China), and direct-to-consumer distribution channels (LillyDirect). No other large pharma is operating across all five vectors simultaneously. This is what ‘exit velocity’ looks like in practice. For Cardiff clients: Lilly’s BD team is actively processing inbound across all therapeutic areas. Companies in Lilly’s footprint (neuroscience, immunology, cardiometabolic, oncology) should ensure active relationship maintenance with Lilly BD regardless of where they are in their development cycle.
II. APPROVALS
Eli Lilly’s Foundayo™ (orforglipron) | FDA Approval for Obesity | $149–$349/month cash | $25/month commercial insurance | Launch April 6
Second oral GLP-1 approved in the U.S. | 50-day review under National Priority Voucher Program (fastest NME since 2002) | Manufactured in Puerto Rico
The FDA approved Foundayo on April 1 for adults with obesity or overweight with weight-related complications. Key differentiators vs. oral Wegovy: no food or water restrictions (can be taken any time of day), vs. Wegovy pill which requires morning dosing on empty stomach with 30-minute fast. Phase 3 ATTAIN data: 12.4% mean body weight loss at highest dose over 72 weeks vs. 0.9% placebo. Small-molecule non-peptide structure enables easier oral absorption without food requirements. Shipping begins April 6 via LillyDirect; broad retail pharmacy and telehealth availability to follow shortly. Medicare Part D coverage at $50/month starts July 1. Novo Nordisk immediately disputed efficacy comparisons, noting no head-to-head trial. Lilly pre-stocked ~$1.5B in orforglipron API at Puerto Rico manufacturing facility, shielding Foundayo from Section 232 tariff exposure.
Cardiff View: The Foundayo approval is the second major commercial catalyst for Lilly in 2026 (after the Centessa acquisition). The no-restriction dosing profile is a genuine adherence advantage and may make Foundayo the preferred entry-level GLP-1 for patients who have not tried any GLP-1 before, a large, untapped population (fewer than 1 in 10 eligible patients currently on any GLP-1). The $149/month price floor matching oral Wegovy avoids a pricing war for now. The true battleground will be formulary placement, Medicare/insurance coverage breadth, and LillyDirect prescribing experience.
III. FINANCINGS AND CAPITAL FLOW
“We’re certainly seeing a lot less opportunistic offerings, meaning the capital raises in between catalysts. We’re generally advising clients to wait to finance until after meaningful clinical or regulatory news to optimize financing outcomes, at least until volatility moderates.” James Lee, Guggenheim Securities (BioCentury 2Q26 Preview)
Blackstone Life Sciences VI | Private Fund Final Close, A Record $6.3B, Largest Private Life Sciences Fund in History
Oversubscribed at hard cap | 40% larger than predecessor BXLS V ($4.6B, 2020) | $15B total AUM | 86% Phase 3 approval success rate
Blackstone announced the final close of BXLS VI on March 30. Funds equal to more than half the total value of all new life sciences investment funds raised globally in 2025 (William Blair). BXLS deployed ~$2B from the fund in the past 12 months (Teva/duvakitug $400M, Merck/sac-TMT $700M, Alnylam $2B). Deployment pace: $1.5–2B/year. Strategy: late-stage royalty financing and co-development, not early-stage VC. Track record: 34 regulatory approvals, 86% Phase 3 success rate.
Cardiff View: The Blackstone Life Sciences VI close is a structural market event, not just a fund story. It means the most disciplined and best-capitalized alternative capital platform in life sciences now has $6.3B freshly committed for late-stage co-development and royalty deals. Combined with Royalty Pharma’s $500M J&J deal this week, alternative capital is establishing itself as the third mainstream financing option for late-stage biopharma development alongside traditional VC and strategic partnerships. Cardiff recommends every client with late stage Phase 2b or Phase 3 assets include Blackstone Life Sciences in their capital strategy discussion.
Private Venture Rounds
IPO Market Activity | Market Volatility
BioCentury’s IPO analysis (April 3) is unambiguous: IPOs are on hold until the U.S.-Iran conflict resolves. 1Q26 produced mixed results. Top performers included IMBiologics (+110%), Kanaph (+85%), and Veradermics (+271% ) alongside meaningful decliners. The IPO queue is dominated by Chinese biotechs pursuing HKSE listings; only Kailera, Alamar, Medikra, and Option Therapeutics represent near-term U.S. candidate listings. BMO Capital Markets’ Marc Ogborn: if the Iran war ends quickly, a wave of IPOs could follow even in April; if conflict persists, a slower return awaits market stabilization.
IV. RISK FACTORS
U.S.-Iran Military Conflict: The Dominant 2Q26 Macro Variable
The U.S.-Iran military conflict, which began in late February 2026, has closed the Strait of Hormuz and pushed Brent crude above $100/barrel for the first time since summer 2022. The S&P 500 fell 4.6% in Q1 2026 (worst quarter since Q1 2022); NASDAQ fell 7.1%. Biotech held materially better. The XBI ended flat from Feb 27 to March 31 while S&P 500 fell 5% (BioCentury data). The conflict’s key biopharma supply chain risks: (1) Generic drug supply: India produces ~50% of U.S. generic prescriptions and relies on the Strait of Hormuz for API inputs; (2) Clinical trial cold-chain biologics in the region; (3) Helium supply (Qatar, critical for MRI and semiconductors). The worst-case scenario is prolonged conflict driving inflation, interest rate reversals, and stagflation, which would meaningfully increase the cost of capital and disproportionately hurt pre-revenue smid-caps.
Cardiff View: The key differentiator for biopharma vs. the broader market is drug demand inelasticity, patients don’t stop needing medicines when oil prices rise. This makes large-cap commercial-stage biopharma a potential safe haven in a flight-to-quality environment. However, pre-revenue smid-caps with short runways face the same cost-of-capital headwind as any growth equity. The BioCentury best-case/worst-case scenario analysis provides the right planning framework: clients should model both outcomes in their 2Q26 financial planning and ensure they are not dependent on public market access within the next 6–12 months.
Section 232 Pharmaceutical Tariffs | 100% on Imported Branded Drugs
Trump signed the Section 232 pharmaceutical tariff executive order on April 2. Baseline: 100% tariffs on patented drugs and APIs. Key exemptions: (1) MFN pricing deal with HHS + U.S. manufacturing onshoring commitment = 0% through January 2029; (2) EU, Japan, South Korea, Switzerland = 15%; (3) U.K. = lower rate; (4) Generics, biosimilars, orphan drugs = exempt. Implementation timelines: large companies 120 days, smaller companies 180 days. The Midsized Biotech Alliance (MBAA consisting of Alnylam, BioMarin, Exelixis, Incyte) immediately filed legal action, arguing the tariff structure favors large pharma. BIO President John Crowley called it a threat to patient access and small biotech innovation.
Cardiff View: (1) Map your API sourcing by country of origin against the tariff rate schedule today and know whether each API comes from a 0%, 15%, or 100% jurisdiction; (2) Evaluate MFN deal eligibility with HHS if you have commercially approved products; (3) Re-underwrite any in-licensing or manufacturing partnership deals that assumed offshore API economics; (4) Do not rely on the MBAA legal challenge as a planning assumption, model compliance in parallel; (5) Consider U.S. manufacturing investment timelines against the January 2029 exemption deadline.
V. 2Q2026 OUTLOOK
BioCentury’s 2Q26 framework identifies three dominant sector-specific variables: (1) U.S.-Iran conflict resolution timeline; (2) FDA predictability post-Prasad departure (end of April); (3) continued M&A deal flow. Cardiff adds a fourth: (4) tariff implementation and MFN negotiation timeline. Here is our guidance mapped to each audience:
VI. WHAT WE ARE WATCHING
SOURCES
BioPharma Dive · MedTech Dive · MedCity News · BioSpace · Fierce Biotech · GlobeNewswire · Endpoints News · DealForma · Pitchbook · BioCentury · STAT News · Cardiff Advisory Research April 4, 2026
Disclosure
Cardiff Advisory LLC is an M&A investment banking, strategic advisory and valuation firm focused on the Life Sciences and Healthcare sectors. This article is provided for informational purposes only and does not constitute an offer, invitation, or recommendation to buy, sell, subscribe for or issue any securities.
The principals of Cardiff Advisory LLC are registered representatives of BA Securities, LLC Member FINRA SIPC, located at Four Tower Bridge, 200 Barr Harbor Drive, Suite 400 W. Conshohocken, PA 19428. Cardiff Advisory LLC and BA Securities, LLC are unaffiliated entities. All investment banking services and securities are offered through BA Securities, LLC, Member FINRA SIPC.
© 2026 Cardiff Advisory LLC.